Which CLL patients would benefit from intensive therapy?
Triple therapy including nivolumab for newly diagnosed AML
Obinutuzumab/chlorambucil gives OS benefit over rituximab in frontline CLL
Overview of novel restore and target treatment approach to classical Hodgkin lymphoma
Biomarkers for acute myeloid leukemia (AML) – lessons from IL-2 immunotherapy with HDC